Simulations Plus, Inc.
simulations-plus.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2026 10-Q, filed Jul 9, 2026. Its latest SEC filing is a 15-12G from Oct 16, 2026.
10-Q for Q3 FY2026, filed Jul 9, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Sells software for modeling drug discovery and development, alongside scientific consulting and clinical-trial training for pharmaceutical and biotechnology companies, hospitals, universities, and government agencies.
10-K for FY2025, filed Dec 1, 2025
How Did They Make Money?
Clients buy software licenses, usually for a year or less, and consulting clients pay as project work is performed.
10-K for FY2025, filed Dec 1, 2025
-
10-K for FY2025, filed Dec 1, 2025
FY2025 revenue by product or service ↗
$79.2M
-
10-K for FY2025, filed Dec 1, 2025
$79.2M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Software
Sold outright
10-K for FY2025, filed Dec 1, 2025 |
58%
FY2022: 61%
|
Software, FY2025
$45.8M Sources
|
Sold outright |
|
Services
Recurring
10-K for FY2025, filed Dec 1, 2025 |
42%
FY2022: 39%
|
Services, FY2025
$33.4M Sources
|
Recurring |
Who Were Their Customers?
Pharmaceutical, biotechnology, and other research companies, along with universities, hospitals, and government agencies, buy software and consulting through the company’s sales team. Independent distributors sell its products in Japan, China, India, South Korea, and Brazil.
10-K for FY2025, filed Dec 1, 2025We provide end-to-end offerings across the drug development lifecycle, including guiding early drug discovery, establishing pre-clinical…View ↗
Our sales and marketing efforts are handled primarily internally by our sales and marketing staff, with our scientific team and several…View ↗
CLIENTSView ↗
10-K for FY2025, filed Dec 1, 2025
Revenue concentration shows that international sales accounted for 27%, 28%, and 31% of revenue for the fiscal years ended August 31, 2025…View ↗
Did Revenues Turn Into Profits?
Not on paper. It lost $64.7M in FY2025, but brought in more cash than it spent: $17.4M of free cash flow.
10-K for FY2025, filed Dec 1, 2025
−$70.7MView ↗
10-K for FY2025, filed Dec 1, 2025
−$64.7MView ↗
10-K for FY2025, filed Dec 1, 2025
$17.4MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Jul 9, 2026
$3.6MView ↗
- ▲ Now profitable
- vs −$67.3M in Q3 FY2025
10-Q for Q3 FY2026, filed Jul 9, 2026
Open tableView ↗
-
Aug 13, 2026
The merger’s antitrust waiting period expired
Shareholder approval and certain regulatory approvals in France are still required.
Sources
8-K, filed Aug 13, 2026
As previously announced, on June 16, 2026, Simulations Plus, Inc., a California corporation (the “Company”), entered into an Agreement and…View ↗
-
Jun 16, 2026
Altaris agreed to acquire Simulations Plus
The planned transaction would combine the company with Chemical Computing Group.
Sources
8-K, filed Jun 16, 2026
RESEARCH TRIANGLE PARK, NC, June 16, 2026 – Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in…View ↗
Grew. Revenue grew 70% in 4 years, from $46.5M in FY2021 to $79.2M in FY2025, about 14% a year.
Clinical-trial training software
The latest report describes Pro-ficiency, a platform for clinical-trial education and protocol compliance; the older report describes software products for pharmaceutical research and development.
10-K for FY2022, filed Oct 28, 2022We currently offer thirteen software products for pharmaceutical research and development as follows:View ↗
Who Did They Compete With?
Competes with Optibrium, Certara, ICON, Metrum Research Group, Veeva, and WCG
10-K for FY2025, filed Dec 1, 2025Major pharmaceutical companies conduct drug discovery and development efforts through their internal development staff and outsourcing.…View ↗
Loading...
